Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02771340 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

A Phase 1 study of Uveal Melanoma and Choroid Neoplasm, sponsored by Iconic Therapeutics.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
8
Study locations

NCT02771340: Completed Phase 1 study of Uveal Melanoma and Choroid Neoplasm, sponsored by Iconic Therapeutics.

NCT02771340 is a Phase 1 study of Uveal Melanoma and Choroid Neoplasm that has completed, run by Iconic Therapeutics. The registered enrollment target is 10 participants, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02771340, a Phase 1 study of Uveal Melanoma and Choroid Neoplasm, has completed, sponsored by Iconic Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.

Conditions Studied

Uveal Melanoma Choroid Neoplasm

Interventions

  • BIOLOGICAL ICON-1

Study Locations (8)

Michigan

  • - Grand Rapids
  • - Royal Oak

California

  • - San Francisco

Colorado

  • - Denver

Kansas

  • - Leawood

Massachusetts

  • - Boston

Oregon

  • - Portland

Pennsylvania

  • - Philadelphia

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-05
Est. Completion 2017-09
Phase Phase 1
Iconic Therapeutics

4 total trials

What the finished NCT02771340 record still lists

NCT02771340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 145-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which ICON-1 is the first listed.

NCT02771340 lists 8 locations in 7 states (Michigan, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT02771340 about?

NCT02771340 is a clinical study titled "Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma". The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the ...

What is the current status of trial NCT02771340?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-05. Estimated completion is 2017-09.

What conditions does trial NCT02771340 study?

This clinical trial studies the following conditions: Uveal Melanoma, Choroid Neoplasm.

What interventions are being tested in trial NCT02771340?

The interventions under investigation include: ICON-1 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02771340?

This trial is sponsored by Iconic Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02771340 being conducted?

This trial has 8 study locations across California, Colorado, Kansas, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02771340's enrollment target sits among peer trials

10 27th of 29 higher than 2 of 29 other Uveal Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02771340, the US trial registry maintained by the National Library of Medicine. NCT02771340 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.